Dergiler / European Archives of Medical Research / 2022 / Cilt: 38 - Sayı: 2

The Utility of Ga-68 DOTA-TATE PET/CT on Clinical Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

Sayfa
132–137
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Patients with a positive scan were also evaluated for peptide receptor radionuclide therapy as an alternative treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Gallium (Ga)-68 DOTA-TATE positron emission tomography/computed tomography (PET/CT) is successfully used for imaging gastroenteropancreatic-neuroendocrine tumors (GEP-NET) and guiding treatment management especially in cases with heterogeneous morphology.
📊
Temel Bulgular & Veri:Methods: Sixty-nine patients (29 women, 40 men) with well-differentiated GEP-NET were referred to our department for Ga-68-DOTA-TATE PET/CT scan analyzed retrospectively.
💡
Sonuç & Katkı:Patients with a positive scan were also evaluated for peptide receptor radionuclide therapy as an alternative treatment.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Gallium (Ga)-68 DOTA-TATE positron emission tomography/computed tomography (PET/CT) is successfully used for imaging gastroenteropancreatic-neuroendocrine tumors (GEP-NET) and guiding treatment management especially in cases with heterogeneous morphology. This study investigates the effect of DOTA-TATE PET/CT on therapy management in GEP-NET. Methods: Sixty-nine patients (29 women, 40 men) with well-differentiated GEP-NET were referred to our department for Ga-68-DOTA-TATE PET/CT scan analyzed retrospectively. Patients were scanned for staging (n=18), re-staging (n=36) and evaluation for treatment response (n=15). Treatment decisions were blindly correlated before and after PET/CT scan. Results: The mean age was 56.63±13.03 (27-79) years. Patients had grade 1 (n=38) grade 2 (n=24) and grade 3 (n=7) tumors. More than half of the patients (53%) had positive findings for primary tumor and/or metastases. Thirteen patients with grade 2; 18 patients with grade 1; 6 patients with grade 3 tumors had positive findings with PET/CT scan. Primary tumors were in the pancreas, stomach, small bowel, appendix and colon. Additionally, metastases in liver, bone, lung, regional and distant lymph nodes were detected. Nineteen of 69 patients (27.5%) had a change in their treatment protocol. The highest change rate was detected at the group with grade 3 tumors. Conclusion: Ga-68-DOTA-TATE PET/CT was shown as a successful method for imaging and guiding management of GEP-NET. The highest benefit in the treatment plan has been shown in patients with grade 3 tumors and group in the follow-up. Patients with a positive scan were also evaluated for peptide receptor radionuclide therapy as an alternative treatment.

🔖

Bu Makaleye Atıf Yap

EKMEKÇİOĞLU, Ö., KAPLAN, N. B. (2022). The Utility of Ga-68 DOTA-TATE PET/CT on Clinical Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). European Archives of Medical Research, Cilt: 38 - Sayı: 2, 132–137. https://ajindex.com/articles/510291

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104:1590-602
  2. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 2011;13:583-93
  3. Kos-Kudła B, Ćwikła J, Ruchała M, Hubalewska-Dydejczyk A, Jarzab B, Krajewska J, et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemp Oncol (Pozn) 2017;21:115-22
  4. Kulkarni HR, Baum RP. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/ CT. PET Clin 2014;9:83-90
  5. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012;42:80-7
  6. Tan TH, Boey CY, Lee BN. Impact of 68Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumour (GI-NET): Malaysian National Referral Centre Experience. Nucl Med Mol Imaging 2018;52:119-24
  7. Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med 2014;55:1811-7
  8. Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2021;48:3260-7
  9. Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 2011;197:1221-8
  10. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 2012;56:40-7
  11. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl